Paridiprubart

N/A

Report date: 2025/11/03 20:01:55
First In Class

Base Information

Drug NameParidiprubart
Drug Alias NameEB-05EB-07NI-0101
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionToll like receptor 4 antagonists
TargetsToll like receptor 4
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Respiratory Distress Syndrome, AdultPulmonary Fibrosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesNetherlands
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesNovimmune Sa
China Registration ClassN/A

Develop Information

Active CompaniesPPD Development LPEdesa Biotech Inc
Inactive CompaniesLight Chain Bioscience Ltd
Active IndicationsRespiratory Distress Syndrome, AdultPulmonary Fibrosis
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)

Other Information

ATC CodeN/A
Related LinksN/A